ku, do not complain about that. CEO King EXPLICITLY said that they would not look at the PPS but run the company in function of the Science and clinical programs until they got to a commercial phase (were they are not).
We are invested in a Small Cap Biotech and you cannot apply the PPS rules to it of quarterly reporting companies that are judge by turn-over/revenue/profits/etc.
Market Data 
Markets 
AI
